Pulmonary Atresia Diagnostics and Treatment Market Research Report – Forecast to 2027

Global Pulmonary Atresia Diagnostics and Treatment Market: Type (Intact Ventricular Septum, Ventricular Septum Defect), Diagnosis (Pulse Oximetry, Echocardiogram), Treatment (Medication, Surgery), End-Users (Hospitals, Clinics)–Global Forecast Till 2027

ID: MRFR/Pharma/5025-HCR | | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario

The global pulmonary atresia diagnostics and treatment market is expected to register a significant growth during the forecast period (2018–2023).

Pulmonary atresia is the type of inherited heart defect that a baby is born with. It arises when the pulmonary valve normally located between the right ventricle and the pulmonary artery doesn’t form properly. The valve should have three leaflets which allow the blood to flow forward into the pulmonary artery but prevent it from flowing backward into the right ventricle. In the case of congenital pulmonary atresia patients, the valve either malfunctions or does not form at all. The tissue formed in the place of pulmonary valve does not allow the blood flow into the pulmonary artery. This flaw develops in the first eight weeks of pregnancy and disturbs the flow of blood from the right ventricle to the pulmonary artery leading to the lungs. It can be recognized in a prenatal ultrasound.

The most common symptoms are blue or gray-toned skin, troubled breathing, weakness, sleepiness, and others. Factors such as technological advancements, increasing awareness, lifestyle changes are the major driving factors for the growth of the market. However, unspecified regulatory issues, infection risks connected with surgical procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Additionally, restrains for the market include the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the pulmonary atresia diagnostics and treatment market negatively.

Segmentation

The global pulmonary atresia diagnostics and treatment market has been segmented on the basis of type, diagnosis, treatment and end users.

On the basis of type, the market has been classified as pulmonary atresia with an intact ventricular septum and pulmonary atresia with ventricular septum defect.

On the basis of diagnosis, the market has been classified as pulse oximetry, electrocardiogram (ECG), echocardiogram (cardiac ultrasound), cardiac MRI and cardiac catheterization.

On the basis of treatment, the market has been classified as medication, cardiac catheterization, surgery. The cardiac catheterization is segmented into radiofrequency ablation and balloon valvotomy, balloon atrial septostomy, and stent placement. The surgery is segmented into right ventricular outflow reconstruction, blalock-taussig shunt, bi-directional glenn procedure, fontan procedure, and heart transplant.

On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, research institutes, and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

The European pulmonary atresia diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The pulmonary atresia diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The pulmonary atresia diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Global Pulmonary Atresia Diagnostics and Treatment Market Share, by Region, 2017 (%)

Pulmonary Atresia Diagnostics and Treatment Market Share

Source: MRFR Analysis

In the pulmonary atresia diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into medical devices manufacturing. According to the Centers for Disease Control and Prevention, about 40,000 births are affected by congenital heart defects in the US every year.

The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to the Centers for Disease Control and Prevention, congenital heart defects are a foremost cause of birth defect associated with infant illness and deaths. The deaths often occur when the infant is less than 28 days old and hence diagnosis of the defect is utmost important.

Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure.

The market in the Middle East & Africa is expected to account for the smallest share of the global pulmonary atresia diagnostics and treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global pulmonary atresia diagnostics and treatment market are Kyowa Pharma Chemical Co. Ltd, AZAD partners, Abbott Laboratories, Dickinson and Company, Becton, C. R. Bard, Inc., B. Braun Melsungen AG, Medtronic plc., Teleflex Incorporated, JOHNSON & JOHNSON, Cook Group Incorporated, and Boston Scientific Corporation.

Global Pulmonary Atresia Diagnostics and Treatment Market, by Type

Pulmonary atresia with an intact ventricular septum

Pulmonary atresia with ventricular septum defect

Global Pulmonary Atresia Diagnostics and Treatment Market, by Diagnosis

Pulse oximetry

Electrocardiogram (ECG)

Echocardiogram (cardiac ultrasound)

Cardiac MRI

Cardiac catheterization

Global Pulmonary Atresia Diagnostics and Treatment Market, by Treatment

Medication

Cardiac catheterization

Radiofrequency ablation

Balloon valvotomy

Balloon atrial septostomy

Stent placement

Surgery

Right ventricular outflow reconstruction

Blalock-Taussig Shunt

Bi-directional Glenn procedure

Fontan procedure

Heart transplant

Global Pulmonary Atresia Diagnostics and Treatment Market, by End-Users

Hospitals

Clinics

Diagnostic centers

Specialty Clinics

Research Institutes

Others

Global Pulmonary Atresia Diagnostics and Treatment Market, by Region

Americas

North America

Canada

South America

Europe

Western Europe

Germany

France

Italy

Spain

Rest of Western Europe

Eastern Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

Middle East & Africa

Middle East

Africa

Intended Audience

Governmental Agency

Educational Organizations

Medical Device Manufacturers

Research Institutes and Academic Centers

Market Research and Consulting

Frequently Asked Questions (FAQ) :

What is Pulmonary Atresia?

Pulmonary atresia is an inherited, congenital heart defect in which the pulmonary valve between the right ventricle and the pulmonary artery doesn’t form or function properly.

What are the major diagnostic methods for Pulmonary Atresia?

Major ways of diagnosing Pulmonary Atresia are ECG, pulse oximetry, cardiac ultrasound, cardiac MRI, and cardiac catheterization.

What is the major driver for the Pulmonary Atresia Diagnostics and Treatment Market?

Growing awareness about inherited diseases is likely to be the major driver for the Pulmonary Atresia Diagnostics and Treatment Market.

Which is the leading regional for Pulmonary Atresia Diagnostics and Treatment Market?

North America is anticipated to account for the largest share in the global Pulmonary Atresia Diagnostics and Treatment Market.

What are the leading Pulmonary Atresia Diagnostics and Treatment Market players

Leading players in the market include Abbott, AZAD Partners, and C.R. Bard, among others.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Pulmonary Atresia Diagnostics and Treatment Market, by Type

6.1 Introduction

6.2 Pulmonary atresia with intact ventricular septum